This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
by Sundeep Ganoria
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
JAZZNegative Net Change TLRYNegative Net Change
biotechs marijuana medical pot-stocks
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
by Ekta Bagri
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
BIIBNegative Net Change IRWDNegative Net Change BMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMYNegative Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
by Zacks Equity Research
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
BIIBNegative Net Change LLYPositive Net Change PRTANegative Net Change
biotechs
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
by Zacks Equity Research
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change MURAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
by Zacks Equity Research
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change DTILNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
by Zacks Equity Research
Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.
RHHBYNegative Net Change SRPTNegative Net Change ANIPPositive Net Change CTMXNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Pfizer Halts Obesity Pill Development Amid Safety Concerns
by Zacks Equity Research
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
PFENegative Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
by Zacks Equity Research
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
LLYPositive Net Change BAYRYNegative Net Change ADMANegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
by Ahan Chakraborty
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
PFENegative Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
by Zacks Equity Research
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
BMYNegative Net Change FOLDNegative Net Change CYTKPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Summit Therapeutics Stock Soared 15% on Friday
by Zacks Equity Research
The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.
MRKPositive Net Change SMMTPositive Net Change TILNegative Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
by Zacks Equity Research
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
BAYRYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
JAZZNegative Net Change ARCTPositive Net Change ADMANegative Net Change KRYSNegative Net Change
biotechs
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
by Zacks Equity Research
The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
by Zacks Equity Research
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
PFENegative Net Change ANIPPositive Net Change ETNBNegative Net Change PCVXPositive Net Change
biotechs medical pharmaceuticals vaccines
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
by Zacks Equity Research
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
JAZZNegative Net Change TGTXNegative Net Change KRYSNegative Net Change DTILNegative Net Change
biotechs
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
by Zacks Equity Research
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change PHIOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
by Zacks Equity Research
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change ANIXNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
by Zacks Equity Research
Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.
ANIPPositive Net Change CTMXNegative Net Change ETNBNegative Net Change VALNNegative Net Change
biotechs medical
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On
by Urmimala Biswas
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.
ABTPositive Net Change BMRNNegative Net Change UHSNegative Net Change
biotechs medical medical-devices pharmaceuticals
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
BMYNegative Net Change AMGNPositive Net Change SRPTNegative Net Change PCRXPositive Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
by Zacks Equity Research
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
BMYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
by Zacks Equity Research
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
FOLDNegative Net Change ANIPPositive Net Change NCNANegative Net Change RLYBNegative Net Change
biotechs